NCT06011850

Brief Summary

This study aims to determine the most effective and long-lasting pain relief method for post-operative analgesia in kidney donor and recipient patients in kidney transplantation programme with the least invasive and least drug administration. For this reason, it is planned to perform Quadratus lumborum plane block (QLB) in a group of patients who will be kidney donors and kidney recipients in kidney transplantation and who meet the American Society of Anesthesiologists (ASA) Physical Status Classification System 1-3 risk classification between the ages of 18-70 years, and to administer intravenous pain medication without block in another group. It is planned to include at least 84 patients in the Quadratus lumborum plan block (QLB) and Intravenous Analgesia group (IVA) without gender discrimination. Postoperative Sedation-Agitation assessment and NRS (numeric pain scale) at 1st hour, 2nd, 6th, 12th and 24th hours, as well as possible side effects such as nausea, vomiting, shoulder pain, respiratory depression, bradycardia and hypotension, total amount of opioid analgesics consumed within 24 hours and duration of hospital stay will be observed and recorded.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
94

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 8, 2023

Completed
17 days until next milestone

First Posted

Study publicly available on registry

August 25, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

October 3, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 6, 2024

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 7, 2024

Completed
Last Updated

February 26, 2025

Status Verified

February 1, 2025

Enrollment Period

7 months

First QC Date

August 8, 2023

Last Update Submit

February 24, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Assessment of pain (NRS) level

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable"

    postoperative 1st, 2nd, 6th, 12th, 24th hours

Secondary Outcomes (9)

  • Sedation- agitation level

    Will be assessed from immediately after extubation until transfer from the recovery room to the ward.

  • Duration of first analgesic requirement

    During the 24 hours postoperative period

  • Blood pressure measurement

    It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.

  • Measurement of heart rate

    It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.

  • Amount of fentanyl consumed during the operation

    During surgery

  • +4 more secondary outcomes

Study Arms (4)

Kidney Donor QLB Group

Quadratus lumborum block (QLB) will be applied to the kidney donor in kidney transplant surgery immediately after induction of general anesthesia before the surgical incision is started.

Kidney Donor Paracetamol Group

In kidney transplantation surgery, 1000 milligrams of Paracetamol will be administered intravenously to the kidney donor before the surgical incision is started, immediately after induction of general anesthesia.

Kidney Recipient QLB Group

Quadratus lumborum block (QLB) will be applied to the kidney recipient in kidney transplant surgery immediately after induction of general anesthesia before the surgical incision is started.

Kidney Recipient Paracetamol Group

In kidney transplantation surgery, 1000 milligrams of Paracetamol will be administered intravenously to the kidney recipient before the surgical incision is started, immediately after induction of general anesthesia.

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Being a kidney recipient and donor in an organ transplant program

You may qualify if:

  • Patients aged 18-70 years,
  • American Society of Anesthesiologists (ASA) Physical Status Classification System I-III,
  • Being a volunteer kidney recipient or volunteer donor in a kidney transplant programme under general anaesthesia

You may not qualify if:

  • Age \<18 years or \> 70 years
  • American Society of Anesthesiologists (ASA) Physical Status Classification System \>III
  • body mass index (BMI) \> 35 kg/m2
  • known allergy to local anaesthetics or paracetamol/tramadol
  • presence of preoperative chronic pain
  • presence of accumulated fluid or cystic formation in the abdomen
  • presence of coagulopathy
  • those who are unable to give written consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

Diyarbakır, 21070, Turkey (Türkiye)

Location

Related Publications (1)

  • Sindwani G, Sahu S, Suri A, Sureka S, Thomas M. Efficacy of ultrasound guided quadratus lumborum block as postoperative analgesia in renal transplantation recipients: A randomised double blind clinical study. Indian J Anaesth. 2020 Jul;64(7):605-610. doi: 10.4103/ija.IJA_21_20. Epub 2020 Jul 1.

    PMID: 32792737BACKGROUND

Study Officials

  • Fatma Acil, M.D.

    Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 8, 2023

First Posted

August 25, 2023

Study Start

October 3, 2023

Primary Completion

May 6, 2024

Study Completion

May 7, 2024

Last Updated

February 26, 2025

Record last verified: 2025-02

Locations